07:26 AM EDT, 05/03/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Thursday it received a $50 million milestone payment from Royalty Pharma ( RPRX ) after completion of the enrollment of a phase 3 trial of olpasiran, a potential cardiovascular disease treatment, conducted by Amgen ( AMGN ) .

Under a 2016 agreement with Amgen ( AMGN ) and a 2022 deal with Royalty Pharma ( RPRX ), Arrowhead said it is eligible to receive up to an additional $375 million from Amgen ( AMGN ) and $110 million from Royalty Pharma ( RPRX ) in development, regulatory and sales milestones.

The drug uses Arrowhead RNA interference technology licensed to Amgen ( AMGN ).

Shares of the company were up 1.5% in recent Friday premarket activity.